Blade Air Mobility Reports Q1 2025 Financial Results

Harvard Bioscience ( (HBIO) ) has released its Q1 earnings. Here is a breakdown of the information Harvard Bioscience presented to its investors.

Blade Air Mobility, Inc. is a New York-based company specializing in air transportation and logistics, primarily focusing on transporting human organs for transplant and providing passenger services in the Northeast United States and Southern Europe. The company operates with an asset-light model and aims to transition to Electric Vertical Aircraft (EVA) for quieter, emission-free air mobility.

In its first quarter of 2025, Blade Air Mobility reported a net loss improvement to $3.5 million and a significant increase in Adjusted EBITDA by $2.3 million compared to the previous year. The Passenger Segment achieved its first profitable quarter since going public, with a 42% revenue increase year-over-year, excluding the impact of its exit from Canada. The Medical segment also set a new monthly record for trip volumes in April 2025.

Key financial highlights include a 5.4% increase in total revenue to $54.3 million, with a notable 18.1% rise in flight profit. The Passenger segment saw a 22.0% flight margin improvement, while the Medical segment experienced a slight decline in revenue. Blade’s strategic initiatives, such as restructuring in Europe and exiting the Canadian market, contributed to these gains. The company ended the quarter with $120 million in cash and short-term investments.

Looking ahead, Blade Air Mobility reaffirms its guidance for 2025, expecting double-digit millions in Adjusted EBITDA. The company plans to continue optimizing its fleet’s operational and financial performance and is positioned to capitalize on strategic investments, particularly in its Medical segment. Despite economic uncertainties, Blade remains confident in its asset-light model and its ability to adapt to market changes.